0.74%
14.19%
12.55%
22.30%
13.51%
1.06%
44.47%
AI Spotlight on ABT
Company Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories.The Nutritional Products segment provides pediatric and adult nutritional products.The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders.
Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Market Data
| Last Price | 128.81 |
| Change Percentage | 0.74% |
| Open | 127.99 |
| Previous Close | 127.86 |
| Market Cap ( Millions) | 223416 |
| Volume | 4757470 |
| Year High | 129.85 |
| Year Low | 99.71 |
| M A 50 | 116.09 |
| M A 200 | 111.03 |
Financial Ratios
| FCF Yield | 2.90% |
| Dividend Yield | 1.74% |
| ROE | 14.74% |
| Debt / Equity | 37.64% |
| Net Debt / EBIDTA | 69.00% |
| Price To Book | 5.61 |
| Price Earnings Ratio | 38.74 |
| Price To FCF | 34.45 |
| Price To sales | 5.42 |
| EV / EBITDA | 21.46 |
News
- Jan -29 - My Best Dividend Aristocrats For February 2025
- Jan -28 - Reasons to Retain ABT Stock in Your Portfolio Now
- Jan -27 - Is There More Upside For ABT Stock After A 10% Jump In A Week?
- Jan -26 - Abbott Laboratories: Strong Q4 Results And Bullish Outlook
- Jan -24 - Abbott Laboratories Will Outperform Healthcare Stocks in 2025
- Jan -24 - What Can The Dividend Kings Deliver In 2025?
- Jan -23 - Why Is Abbott Stock Trading Higher On Thursday?
- Jan -23 - Two Contrarian Dividends With Triple-Digit Potential For Trump 2.0
- Jan -23 - Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
- Jan -23 - My Top 5 Stocks to Buy in Early 2025
- Jan -22 - Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
- Jan -22 - Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
- Jan -22 - Compared to Estimates, Abbott (ABT) Q4 Earnings: A Look at Key Metrics
- Jan -22 - Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
- Jan -22 - Abbott (ABT) Q4 Earnings Meet Estimates
- Jan -22 - Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates
- Jan -22 - Abbott forecasts in line annual profit on medical device sales
- Jan -22 - Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
- Jan -21 - Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
- Jan -20 - HAE or ABT: Which Is the Better Value Stock Right Now?
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Medical Devices
Expected Growth : 5 %
What the company do ?
Abbott Laboratories' medical devices include pacemakers, implantable cardioverter-defibrillators, and neurostimulators for chronic pain management and movement disorders.
Why we expect these perspectives ?
Abbott Laboratories' Medical Devices segment growth is driven by increasing demand for minimally invasive treatments, expanding indications for existing products, and geographic expansion in emerging markets. Additionally, the company's focus on innovation, strategic acquisitions, and partnerships contribute to its growth momentum.
Segment n°2 -> Diagnostic Products
Expected Growth : 4 %
What the company do ?
Diagnostic Products from Abbott Laboratories provide innovative solutions for medical professionals to diagnose and monitor various health conditions, including infectious diseases, cancer, and cardiovascular diseases.
Why we expect these perspectives ?
Abbott's Diagnostic Products segment growth is driven by increasing demand for molecular diagnostics, expansion in emerging markets, and strategic acquisitions. The company's Alinity platform and rapid diagnostics tests for infectious diseases, such as COVID-19, are contributing to growth. Additionally, the segment benefits from a strong pipeline of new products and geographic expansion, particularly in Asia and Latin America.
Segment n°3 -> Nutritional Products
Expected Growth : 3 %
What the company do ?
Abbott Laboratories' nutritional products include Ensure, Pediasure, and Similac, offering a range of infant formulas, adult nutrition, and pediatric nutrition solutions.
Why we expect these perspectives ?
Abbott's Nutritional Products segment growth is driven by increasing demand for pediatric nutrition in emerging markets, particularly in Asia and Latin America. Additionally, the company's investments in e-commerce and digital marketing are expanding its online presence, while its product portfolio expansion into specialized nutrition and healthy living products is attracting a wider customer base.
Segment n°4 -> Established Pharmaceutical Products
Expected Growth : 7 %
What the company do ?
Established Pharmaceutical Products from Abbott Laboratories include branded generic medicines in therapeutic areas like neuroscience, gastroenterology, and primary care.
Why we expect these perspectives ?
Established Pharmaceutical Products from Abbott Laboratories with 7% growth driven by increasing demand for chronic disease treatments, expanding product portfolio through strategic acquisitions, and growing presence in emerging markets. Additionally, cost savings from operational efficiencies and favorable currency exchange rates contribute to growth.
Segment n°5 -> Other
Expected Growth : 5 %
What the company do ?
The 'Other' segment from Abbott Laboratories includes businesses that do not fit into its established reportable segments, such as its medical optics and Abbott Informatics businesses.
Why we expect these perspectives ?
Abbott's 'Other' segment, with 5% growth, is driven by increasing demand for established pharmaceuticals, expansion into emerging markets, and strategic partnerships. Additionally, the company's diversified portfolio and investments in R&D contribute to its growth momentum.
Abbott Laboratories Products
| Product Range | What is it ? |
|---|---|
| Nutritionals | Abbott's nutrition business provides a range of science-based nutrition products to support healthy growth and development, from infancy to adulthood. |
| Diabetes Care | Abbott's diabetes care business provides a range of glucose monitoring systems and other products to help people with diabetes manage their condition. |
| Established Pharmaceuticals | Abbott's established pharmaceuticals business provides a range of branded generic pharmaceuticals to treat a variety of conditions, including pain, fever, and inflammation. |
| Cardiovascular and Neuromodulation | Abbott's cardiovascular and neuromodulation business provides a range of products to treat cardiovascular and neurological conditions, including heart failure, atrial fibrillation, and chronic pain. |
| Electrophysiology | Abbott's electrophysiology business provides a range of products to diagnose and treat heart rhythm disorders, including atrial fibrillation and ventricular tachycardia. |
| Structural Heart | Abbott's structural heart business provides a range of products to treat structural heart conditions, including mitral regurgitation and aortic stenosis. |
| Vascular | Abbott's vascular business provides a range of products to treat vascular conditions, including peripheral artery disease and carotid artery disease. |
| Point of Care | Abbott's point of care business provides a range of diagnostic testing products to help healthcare professionals make informed decisions at the point of care. |
| Molecular Diagnostics | Abbott's molecular diagnostics business provides a range of molecular diagnostic tests to help diagnose and monitor infectious diseases, including HIV, hepatitis, and influenza. |
| Informatics | Abbott's informatics business provides a range of data management and analytics solutions to help healthcare professionals make informed decisions. |
Abbott Laboratories's Porter Forces
Threat Of Substitutes
Abbott Laboratories operates in a highly competitive industry, and there are many substitutes available for its products. However, the company's strong brand reputation and high-quality products help to mitigate the threat of substitutes.
Bargaining Power Of Customers
Abbott Laboratories has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to patient care, making it difficult for customers to negotiate prices.
Bargaining Power Of Suppliers
Abbott Laboratories relies on a network of suppliers for raw materials and components. While the company has some bargaining power due to its size, suppliers may still have some negotiating power, particularly if they provide specialized or high-quality materials.
Threat Of New Entrants
The pharmaceutical and medical device industries are heavily regulated, and new entrants face significant barriers to entry, including high research and development costs and stringent regulatory requirements.
Intensity Of Rivalry
The pharmaceutical and medical device industries are highly competitive, with many established players competing for market share. Abbott Laboratories faces intense competition from companies such as Johnson & Johnson, Medtronic, and Pfizer.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 27.88% |
| Debt Cost | 4.67% |
| Equity Weight | 72.12% |
| Equity Cost | 7.60% |
| WACC | 6.78% |
| Leverage | 38.66% |
Abbott Laboratories : Quality Control
Abbott Laboratories passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular … |
| BSX | Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company … |
| DXCM | DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems … |
| SYK | Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
J&J
A-Score
1-Year Total Return ->
🥈
Abbott
A-Score
1-Year Total Return ->
🥉
Stryker
A-Score
1-Year Total Return ->
4
Boston Scientific
A-Score
1-Year Total Return ->
5
Regeneron Pharmaceuticals
A-Score
1-Year Total Return ->
6
